p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

Overview of attention for article published in Molecular Cancer Therapeutics, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Average Attention Score compared to outputs of the same age and source

So far, Dimensions has found 1 citation of this research output.

The most recent citing publication is shown below. View this citation on Dimensions.

Article in Biochemical Pharmacology (November 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.